PsyMed Ventures

Jimini Health is a mental health company dedicated to enhancing the effectiveness of mental health care globally. Established in 2023 by a team of experienced professionals in AI, biotech, and psychology, Jimini combines teletherapy with personalized AI support to create a comprehensive care model. Patients receive assistance from licensed clinicians and an AI therapy assistant named Sage, who work collaboratively to help individuals achieve their mental health goals. Jimini emphasizes the importance of clinical oversight and safety, ensuring that its technology is purpose-built and rooted in scientific principles. The company focuses on evidence-based practices and individualized care, particularly for those experiencing persistent anxiety. By integrating advanced technology with expert clinical guidance, Jimini aims to deliver high-quality mental health experiences that empower patients to take proactive steps in their treatment.

Neurode is focused on the development of a non-invasive wearable headset aimed at enhancing cognitive performance for individuals with neurological conditions, particularly ADHD. This innovative device employs electrical stimulation to address the imbalances in brain activity commonly associated with ADHD. Alongside the headset, Neurode offers a companion application that monitors users' progress and shares improvements with healthcare professionals. This drug-free approach seeks to alleviate symptoms such as working memory deficits, attention challenges, and impulse control issues, ultimately enabling better management of cognitive performance for users.

Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.

Remepy is a biotechnology company established in 2022, based in Ramat Gan, Tel Aviv. The company focuses on developing hybrid drugs that integrate traditional pharmaceuticals with tailored software applications. This innovative approach aims to enhance drug efficacy by utilizing Hybrid Mechanisms of Action™, which influence patients' health outcomes through synergetic interactions at the molecular level. By combining medicine and technology, Remepy seeks to enable pharmaceutical companies to offer software-drug combinations that can positively affect the immune system, ultimately improving the safety and effectiveness of treatments.

Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.

Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.

Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.

Mindstate Design Labs is a clinical-stage biotechnology company focused on developing innovative psychedelic-inspired therapeutics aimed at addressing intractable mental health and behavioral conditions. The company employs a unique platform that combines natural history and computational methods to map the biological basis of various psychedelic experiences. This mapping allows Mindstate Design Labs to design psychoactive effects intended for use in medically supervised environments, targeting the root causes of mental health disorders. By utilizing serotonergic agonists, the company seeks to enable healthcare institutions to effectively alter states of consciousness for therapeutic purposes.

Maya Health's mission is to improve psychedelic practitioners with the technology and data they need to scale safely and effectively, serve more people, and advance psychedelic healthcare. The company was founded in 2019 by David Champion and Akoni Anthony and is based in Denver, Colorado.

Freedom Biosciences is a biotechnology platform focused on developing next-generation psychedelic therapeutics. The company aims to create innovative psychedelic pharmaceuticals by utilizing the established pharmacology of ketamine and other psychedelic compounds. This approach is intended to equip medical professionals with effective treatment options for patients suffering from resistant depression and various mental disorders.

Reset Pharmaceuticals is a biotechnology company dedicated to developing and commercializing innovative psychedelic treatments for patients facing life-threatening illnesses, particularly cancer. The company's primary focus is on psilocybin combined with psychotherapy to address issues such as demoralization, anxiety, and depression in patients suffering from cancer. By leveraging advanced technology, Reset Pharmaceuticals aims to create therapeutics that not only improve mental health outcomes for terminal patients but also enhance their overall quality of life.

Tactogen is a biopharma startup based in Palo Alto, California, founded in 2020 by neuroscientist Matthew Baggott and entrepreneur Luke Pustejovsky. The company focuses on developing empathogen medicines, which are designed to promote mental wellness and facilitate emotional connection among individuals. Tactogen's innovative approach centers on creating safer and more effective pharmaceuticals, including novel molecules and drug discovery methods aimed at producing unique emotional states that balance openness and motivation. This research-driven initiative seeks to enhance the efficacy of psychotherapy and other psychological treatments while ensuring that empathogens can be prescribed safely for take-home use.

Freedom Biosciences is a biotechnology platform focused on developing next-generation psychedelic therapeutics. The company aims to create innovative psychedelic pharmaceuticals by utilizing the established pharmacology of ketamine and other psychedelic compounds. This approach is intended to equip medical professionals with effective treatment options for patients suffering from resistant depression and various mental disorders.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.

Beckley Psytech Limited is a company based in Oxford, United Kingdom, that specializes in developing psychedelic drugs aimed at treating psychiatric and neurological diseases. Founded in 2014, the company explores the therapeutic potential of substances such as psilocybin to address mental health issues, including depression and other debilitating neuropsychiatric conditions. Beckley Psytech is focused on integrating clinically validated psychedelic medicines into contemporary medical practices, providing alternative treatments for patients who have significant unmet needs. Through its drug pipeline, the company aims to innovate and differentiate its offerings in the marketplace, enhancing options for individuals suffering from these disorders.

TRIPP Inc. is a company that specializes in developing a digital psychedelic wellness platform utilizing virtual and augmented reality to enhance emotional well-being. Founded in 2016 and headquartered in Los Angeles, California, with a satellite office in Chicago, TRIPP combines audio, visual elements, and gameplay mechanics with mindfulness techniques to create immersive experiences aimed at transforming users' emotional states. The platform is designed based on scientific research, demonstrating that interactive digital experiences can positively impact the brain. Through targeted sound frequencies, visuals, and interactive exercises, TRIPP provides users with tools to manage stress, anxiety, and promote a sense of calm and focus in their daily lives.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Bexson Biomedical is developing a unique formulation of ketamine for chronic and acute pain disorders.

Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.